◈ Nootpedia
Compact view
Research pass: thorough Supplement · Capsule OPTIONAL-ADD MEDIUM

Alpha-GPC (L-Alpha-Glycerylphosphorylcholine)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM

Real, fast-onset acute cognitive enhancement (60-90 min) and replicated growth-hormone + power-output bump pre-workout, but the 2021 Korean nationwide cohort signal (12 M people, dose-dependent stroke aHR 1.43-1.46) plus the mechanistic TMAO-atherogenesis pathway means chronic high-dose daily use is not free; for Dylan, citicoline already covers chronic choline so alpha-GPC is best as PRN pre-task / pre-workout (300-600 mg) rather than daily.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    Citicoline already covers chronic cholinergic substrate (V4 includes 500 mg Cognizin daily); alpha-GPC adds acute pre-task / pre-workout spike that citicoline doesn't deliver as cleanly. Use 300-600 mg PRN before deep work / sales calls / hard training, 2-4× per week. Don't replace citicoline. Confidence: MEDIUM — strong evidence for acute effect, but Lee 2021 stroke signal lurks even if probably overestimated for this profile. Reassess after 23andMe (FMO3, APOE) + bloodwork (lipids, hs-CRP).

  • 20-30, MMA / strength athlete, pre-workout focus
    STRONG-CANDIDATE PRN

    600 mg 60-90 min pre-training: real ~14% peak-force bump, GH augmentation, mind-muscle connection. Stack with caffeine + theanine. Use 2-4×/week on hard training days. Don't take post-3 PM if late chronotype.

  • 30-50, executive maintenance
    OPTIONAL-ADD PRN

    Same use case as Dylan-archetype. Watch lipid drift / hs-CRP if moving to chronic.

  • 50+, MCI / mild cognitive decline
    STRONG-CANDIDATE

    chronic. This is the Italian Rx indication. 1,200 mg/day × 90-180 days has replicated benefit. Monitor stroke risk — discuss with prescriber, ensure BP + lipid + hs-CRP are managed. The 2025 Korean MCI cohort showed *protective* effect in the disease subset, balancing the 2021 prospective signal.

  • 50+, established AD (mild-moderate)
    STRONG-CANDIDATE

    adjunct. De Jesus Moreno 2003 showed cognitive separation from placebo at 1,200 mg/day × 6 months. Italian standard of care. Pair with cholinesterase inhibitor (donepezil) carefully — likely additive but watch for cholinergic excess.

  • Established stroke / TIA history
    CAUTION

    Even though acute post-stroke recovery RCTs show benefit, the 2021 prospective registry signal warrants cardiology + neurology discussion before chronic use. PRN at low dose probably OK; chronic 1,200 mg/day not without reason.

  • Vascular risk factors (HTN, dyslipidemia, smoker, T2DM, family CV history)
    CAUTION

    on chronic high-dose. TMAO concern compounds with existing risk. PRN OK; chronic 1,200 mg/day needs better justification than "general cognition."

  • Anxiety-prone
    NEUTRAL

    Some users feel mild restlessness at 600 mg; most find it cleaner than caffeine. Start at 300 mg.

  • DylanSleep-disordered / late chronotype (Dylan)
    AM

    PM only. Cholinergic activation disrupts sleep onset and increases REM intensity (vivid dreams). No alpha-GPC after 3 PM.

  • High athletic load, WADA-tested status
    NOT WADA BANNED

    Standard pre-workout ingredient. Safe for tested athletes. (Dylan untested — irrelevant for him.)

  • Recovery-focused (post-injury)
    NEUTRAL

    Some role in BPC-157/membrane-repair logic but not a primary recovery driver.

  • Strength / anabolic-focused
    PRN PRE-WORKOUT

    Real GH-pulse augmentation + peak-force boost. Pair with the rest of the pre-workout stack. Don't expect chronic anabolic effect.

  • Bipolar / psychotic-spectrum
    CAUTION

    Cholinergic activation can destabilize mood; case reports of cholinergic-induced depression at high chronic doses.

▸ Subjective experience (deep)

At 300 mg, single oral dose:

  • Onset 30-60 min; peak 60-90 min. Subtle. Some users feel nothing on the first dose, especially if choline-replete from diet (eggs, beef, fish).
  • Mild mental sharpness, slightly faster word recall, easier task initiation. Cleaner than caffeine — no peripheral jitter, no HR change.
  • Duration: 4-6 hours of subjective effect; choline stays elevated longer.

At 600 mg, single oral dose:

  • Stronger, more consistent. Most users describe a "clean stimulant-like" feel — alert, motivated, cognitively crisp without anxiety or sympathetic activation.
  • Pre-workout: better mind-muscle connection, harder mental drive on heavy lifts, occasional users report measurably better lift outputs.
  • Onset: 45-90 min reliably. Peak choline ~1.5 hr.
  • Tail: soft. Effect wanes 4-6 hr post-peak with no significant come-down. Some users report mild mental fatigue 6-8 hr post-dose if they don't follow with food.

At 1,200 mg/day (chronic, divided into 400 mg TID — Italian Rx dose):

  • Less of an acute "feel" because steady-state. More of a baseline cognitive lift, primarily noticed on stopping.
  • At this chronic dose: more headache risk, more GI risk, more "cholinergic excess" risk (sweating, slight bradycardia, mild GI hypermotility, vivid dreams). Some users on long-term 1,200 mg report flat affect, mild dysphoria, irritability — likely from chronic acetylcholine over-tone (cholinergic depression is a documented phenomenon).

Variability:

  • ~70-80% of healthy users feel something at 600 mg single dose. ~20-30% feel nothing.
  • Non-responders are often already choline-replete (high-egg, high-fish, high-meat diets) or have CHAT/CHRM1 polymorphisms that limit acetylcholine synthesis upstream/downstream.
  • Dylan's diet (chicken/rice/avocado, fruit, gluten-free home cooking) is not a choline-rich diet — eggs and beef liver are the highest choline foods, and the profile suggests moderate dietary choline. He should respond to alpha-GPC.
▸ Tolerance + cycling deep dive
  • Acute single-dose effect tolerance: minimal. Repeated weekly PRN dosing remains effective — choline is a substrate, not a receptor agonist, so the underlying ChAT pathway doesn't downregulate the way an agonist-targeted receptor would.
  • Chronic daily tolerance to GH-spike effect: the GH augmentation attenuates within ~4 weeks of daily dosing as the cholinergic-somatostatin axis adapts. For pre-workout GH purposes, intermittent use (2-4×/week, training days only) preserves the effect.
  • Receptor downregulation: at 1,200 mg/day chronically, mild M1/M3 muscarinic downregulation possible (animal data). Not relevant at PRN 300-600 mg.
  • Recommended cycle (Dylan): PRN basis, no formal cycle needed. If chronic daily usage adopted, 8 weeks on / 2-4 weeks off.
▸ Stacking deep dive

Synergistic with

  • caffeine + l-theanine: ✅ The cleanest pre-task / pre-workout combo. Caffeine 100-200 mg + L-theanine 200 mg + alpha-GPC 300-600 mg = adenosine antagonism + α-wave enhancement + acetylcholine support → focus, drive, vigilance without jitter. This is the standard "nootropic stack" most pre-workouts replicate.
  • alcar: ✅ ALCAR provides the acetyl group for ChAT; alpha-GPC provides the choline. Substrate + substrate → maximal acetylcholine production. Already in Dylan's V5 plan (ALCAR 500 mg AM) — alpha-GPC PRN before deep work / training fits cleanly.
  • modafinil: ✅ Modafinil increases cortical activation (orexin, histamine, NE, mild DA) which raises acetylcholine demand; alpha-GPC supplies the substrate. Anecdotally smooths modafinil's "cognitive ceiling" on hard workdays. Stack-safe.
  • bromantane: ✅ Bromantane's tyrosine-hydroxylase upregulation increases dopamine synthesis; alpha-GPC's cholinergic complement balances the DA tilt. Consistent with the V5 framework.
  • l-tyrosine: ✅ Catecholamine substrate; alpha-GPC = cholinergic substrate. Both substrate-replenishment, both PRN under cognitive load. Stack-safe.
  • rhodiola, ashwagandha: ✅ Adaptogens are mechanism-orthogonal. No interaction.
  • DHA / phosphatidylserine: ✅ Both feed neuronal membrane health; alpha-GPC supplies the choline head, DHA the fatty-acid tail. Already in Dylan's V4 (PS 200 mg, DHA 2 g).

Avoid stacking with

  • Citicoline at full 500 mg dose simultaneously: ❌ Redundant. Both elevate plasma choline. Stacking doesn't roughly double the effect — choline transport saturates. Use one, not both. Dylan's V4 has citicoline 500 mg daily; alpha-GPC fits as a replacement on PRN-task days, not a stack-on. Or use citicoline on rest days, alpha-GPC on cognitive/training days.
  • Huperzine A at chronic high dose: ⚠️ Cholinergic excess risk. Alpha-GPC raises acetylcholine; huperzine inhibits its breakdown. Combined: nausea, sweating, bradycardia, mood changes. Short-acting low-dose huperzine PRN with alpha-GPC PRN is generally tolerable; chronic stack of 1,200 mg alpha-GPC + 200 mcg/day huperzine is not advisable.
  • Donepezil, galantamine, rivastigmine (Rx AChE inhibitors): ❌ Same logic as huperzine, more so. Not relevant for Dylan.
  • Nicotine, varenicline: ⚠️ Cholinergic stacking. Alpha-GPC + heavy nicotine = potentiated cholinergic activation. Mild concern, not absolute contraindication.
  • Multiple choline donors simultaneously (alpha-GPC + citicoline + lecithin + choline bitartrate + CDP-choline): ❌ Stacking choline donors past saturation produces depression/dysphoria in some users (the "too much choline" pattern). Pick one primary donor.

Neutral / safe co-administration

  • All current V4 stack items (NAC, magnesium glycinate/threonate, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, fish oil, creatine).
  • All planned V5 additions except duplicate cholinergics (citicoline overlap).
▸ Drug interactions deep dive
  • Anticoagulants / antiplatelets (warfarin, aspirin, clopidogrel): Theoretical concern via TMAO platelet hyperreactivity pathway, but no significant clinical interaction signal. Standard monitoring sufficient.
  • Anticholinergic drugs (oxybutynin, tricyclic antidepressants, first-gen antihistamines like diphenhydramine): Alpha-GPC may partially counter their effects (and vice versa). Not dangerous, just may reduce efficacy of anticholinergic.
  • Beta-blockers (propranolol): No interaction. Stack-safe.
  • Modafinil, armodafinil: No CYP interaction. Stack-safe.
  • Hormonal contraceptives: No interaction.
  • CYP enzymes: Alpha-GPC does not meaningfully induce or inhibit CYP. Pharmacokinetic interactions essentially nil.
  • Valproate / lithium / carbamazepine: No documented interaction. Cholinergic stacking with cholinergic-modulating mood stabilizers is theoretical only.
▸ Pharmacogenomics

Minimal direct PGx data for alpha-GPC specifically. Relevant indirect variants:

  • FMO3 (TMAO production, see ALCAR file for full SNP list): rs2266782 (E158K), rs2266780 (V257M), rs1736557 (E308G). Hypomorphic carriers produce more TMA → less FMO3-mediated conversion to TMAO (paradoxically better CV outcome, worse body-odor outcome — TMAU). Wild-type homozygotes produce maximum TMAO. Relevant for Dylan post-23andMe (June 2026).
  • CHAT (choline acetyltransferase): polymorphisms may modulate acetylcholine synthesis efficiency. Limited clinical data.
  • CHRM1, CHRM2, CHRNA4, CHRNA7 (cholinergic receptors): theoretical modulators of cognitive response to alpha-GPC. Limited data.
  • APOE ε4: Some 2024 work suggests APOE ε4 carriers may benefit more from cholinergic support (cholinergic deficit appears earlier in ε4 carriers). For Dylan: relevant if 23andMe shows ε4 — moves alpha-GPC slightly toward STRONG-CANDIDATE for prophylactic cognitive preservation.
  • CTL1 / SLC44A1 (choline transporter): variants affect choline BBB transport. Rare clinical relevance.

Action for Dylan: When 23andMe results land (~June 5-15, 2026), check FMO3 and APOE ε4. If hypomorphic FMO3, TMAO production lower (less concern). If APOE ε4+, alpha-GPC moves toward chronic-add candidacy alongside citicoline.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC Doublewood Supplements (300 mg × 60 caps) $22 / 60 = **$11/mo** at 300 mg/day, ~$22/mo at 600 mg/day High Third-party tested; clean label; lab CoA available on request. Solid value pick.
OTC Jarrow Formulas (300 mg × 60 caps) $28 / 60 = **$14/mo** at 300 mg/day High Reference-standard brand, USP-style verification. iHerb staple. AlphaSize-grade ingredient.
OTC NOW Foods (300 mg × 60 vcaps) $18 / 60 = **$9/mo** at 300 mg/day High Budget pick. iHerb/Amazon. Reliable.
OTC Bulksupplements (powder, 100 g) $25 / 100 g = **$0.25 per 300 mg dose, ~$2/mo PRN** High Cheapest path. Hygroscopic — store with desiccant. Bitter; mix into water.
OTC Nootropics Depot (300 mg × 90 caps) $30 / 90 = **$10/mo** at 300 mg/day High Third-party CoA published. Premium nootropics vendor.
Rx (international) Italfarmaco Delecit (Italy), Gliatilin (Russia/Korea) ~$30-50/mo at 1,200 mg/day High Pharmaceutical-grade. Requires Rx in country of purchase. Not needed for Dylan's PRN use case.

Recommendation for Dylan: NOW Foods 300 mg × 60 caps via iHerb (~$18, 60 doses). Two caps for 600 mg pre-workout/pre-task = 30 doses per bottle = ~3 months of PRN use at 2-3×/week. Total cost: ~$6/month steady-state. Cheapest path that maintains brand reliability already in his iHerb supply chain.

Total cost estimate (Dylan): ~$5-15/month for PRN use. Negligible relative to V4/V5 budget.

▸ Biomarkers to track (deep)

Baseline (before starting chronic use; not needed for PRN)

  • Lipid panel (total chol, LDL, HDL, ApoB, Lp(a))
  • hs-CRP — baseline inflammation
  • Plasma TMAO (Cleveland HeartLab) — particularly if planning chronic >6 mo at >600 mg/day
  • Blood pressure — baseline (alpha-GPC mildly affects BP transiently; rule out HTN)
  • Homocysteine — methylation status (relevant to choline metabolism)
  • CBC, CMP — general baseline
  • Optional: GH/IGF-1 baseline if interested in tracking the GH-augmentation use case

During use (chronic only, not PRN)

  • Plasma TMAO at 3-6 months — primary safety biomarker for chronic alpha-GPC
  • Lipid panel + hs-CRP at 6 months
  • Subjective tracking: cognition (1-10 scale), mood (irritability/dysphoria check), sleep, GI tolerance — daily for first 4 weeks, then weekly

Post-cycle (if cycled)

  • TMAO at end of washout — should return to baseline; if not, gut microbiome has shifted
▸ Controversies / open debates Live debate
  • Lee 2021 stroke signal interpretation: cohort artifact (confounding-by-indication) vs causal vascular harm. The 2021 paper's registry size makes the signal hard to dismiss; Biffi/Lee critiques and the 2025 MCI sub-cohort (showing protective effect) suggest substantial confounding. My read: signal is real but magnitude overestimated by 30-60%; absolute-risk implication for healthy 20yo PRN users is small but non-zero. For chronic 50+ daily users, the signal is non-trivial.
  • Alpha-GPC vs citicoline head-to-head: 2025 Frontiers Neurology meta showed alpha-GPC superior on global SCAG impression; equivalent on memory. Italian Rx tradition + Korean Rx tradition both favor alpha-GPC for dementia. US nootropics community historically favored citicoline (cytidine bonus, cleaner safety record). Consensus 2025: alpha-GPC is acutely stronger; citicoline is cleaner for chronic daily use given the stroke-signal asymmetry.
  • TMAO causality: Same debate as ALCAR — is TMAO causally atherogenic, or a marker? Mechanistically the case for causality is strong (Wang 2011 Nature, replicated 2025 MESA). Mendelian randomization is mixed but generally supportive. At minimum, TMAO is a reliable risk marker; chronic 30× elevation from any source is a flag.
  • Endurance vs power output: alpha-GPC clearly augments peak power (Ziegenfuss, Bellar, Marcus). Endurance / time-to-exhaustion data is mixed. Mechanism for power: cholinergic NMJ activation. Mechanism for endurance: choline-depletion attenuation, smaller effect.
  • Healthy young adult cognition: older skepticism ("no benefit in healthy adults") is being overturned by 2024 Marcus Stroop RCT and the ~80% subjective-responder anecdotal pattern. Real but moderate effect size (~Cohen d 0.3-0.5), high inter-individual variability driven by baseline choline status.
  • Chronic high-dose mood effects (cholinergic dysphoria): anecdotal; some users on 1,200 mg/day for months report flat affect, irritability, mild depression. Biological plausibility (chronic cholinergic > dopaminergic balance shift) — moderate. Trial data: largely absent. Treat as plausible but unconfirmed.
  • Italian-language 1990s evidence base: ~13 trials, most published in Italian journals, methodologically weaker than modern AD trials. Pooled in 2023 meta but quality of evidence rated moderate-low. De Jesus Moreno 2003 is the keystone; everything else is supporting.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-ADD / PRN. Confidence: MEDIUM. For Dylan, citicoline already in V4 covers the chronic cholinergic role; alpha-GPC fits as PRN pre-cognitive-task and pre-workout spike at 300-600 mg, 2-4×/week. The Lee 2021 stroke signal is real but probably confounded; absolute-risk implication for a 20yo healthy user PRN is small. Daily chronic 600 mg+ would warrant TMAO + lipid monitoring; for PRN use this is overkill.
▸ Open questions / gaps Open
  • Is the Lee 2021 stroke signal causal or confounded by indication? No definitive answer pending. Best evidence: the 2025 MCI sub-cohort showing protective effect suggests substantial confounding-by-indication, but the broader cohort still shows the signal.
  • Does alpha-GPC at PRN 300-600 mg 2-4×/week produce meaningful TMAO accumulation? No data. Mechanistic guess: minimal vs chronic 1,200 mg/day.
  • APOE ε4 modulation: carriers may benefit more from cholinergic support. Pending Dylan's 23andMe.
  • FMO3 genotype effects on alpha-GPC TMAO production specifically: no direct study; extrapolated from carnitine/choline data.
  • Long-term (>5 yr) safety in healthy young adults: essentially none; all long-term data is in MCI/AD/elderly populations.
  • Head-to-head alpha-GPC vs citicoline in healthy young adults for acute cognition: the 2025 Frontiers meta is in dementia. No clean healthy-adult head-to-head exists.
  • Whether chronic alpha-GPC produces cholinergic dysphoria in a measurable fraction of users: anecdotal-only.
  • Whether the GH-spike effect translates to any meaningful body-composition or recovery outcome over weeks-months: Ziegenfuss 2008 was an acute single-session study. No chronic body-comp RCT.
▸ Sources (full, with our context)
Back to compact view